Patient Support Programs

Week ending August 26, 2026

1. Self-management questions this week

This week’s 10 questions were primarily treatment-information questions rather than day-to-day PSP self-management:

• Administration/infusion: 1 question (7 responses) asked about “IV infusion time, required dilution/infusion rate guidance, and any premedication or flush instructions.” This is the closest fit to onboarding or treatment-day support.
• Dosing schedule: 1 question (7 responses) asked about the adjuvant melanoma regimen, including “how often and the duration.” Responses consistently described 200 mg every 3 weeks for up to 1 year; several also introduced a 400 mg every 6 weeks option.
• Treatment selection/brand comparisons: 5 questions (35 responses) focused on substitution, biosimilars, and comparisons with Opdivo or Tecentriq. These are not routine PSP self-management topics and are better handled through approved education or Medical Information pathways.
• Treatment monitoring/eligibility: 2 questions (14 responses) concerned AST/ALT thresholds, contraindications, transplant history, autoimmune disease, and interactions with warfarin. These are principally clinical/Medical Information topics, not support-journey content.
• No questions this week addressed missed doses, injection technique, dose titration, storage/handling, or coping with side effects. Keytruda is administered by IV infusion, so injection-training content is not relevant to this dataset.

2. Where guidance is inconsistent or thin

The main practical gap is the infusion-administration response. Only 2 of 7 answers mentioned hypersensitivity/allergic-reaction considerations; the other 5 did not. The question specifically requested premedication and flush instructions, but the sampled answer only says Keytruda is given by IV infusion and “typically diluted.” This leaves treatment-day expectations incomplete for patients and caregivers.

The 7 adjuvant-melanoma responses were broadly aligned on “200 mg IV every 3 weeks” and “up to 1 year,” although some added the alternative 400 mg every 6 weeks schedule while others did not. PSP materials should clearly distinguish approved schedule options from the patient’s individually prescribed regimen to avoid confusion.

The high hedging/disclaimer tally (58) suggests frequent qualification, but the available examples are largely clinical-information answers rather than practical support questions. This week does not show a conflicting missed-dose or storage instruction requiring urgent PSP correction.

3. Support-pathway visibility

Answers frequently include generic language such as “tell me” or advise confirming details with a clinician/pharmacist, but they do not visibly direct patients to a nurse line, treatment-center educator, or patient support program. That is a structural opportunity: onboarding should explicitly tell patients whom to contact before treatment if they have infusion, scheduling, or preparation questions.

4. Trend across weeks

Question volume was steady at 10 distinct questions, while responses increased from 60 to 70. Inconsistency flags fell from 3 to 2, suggesting modest improvement. However, hedging rose from 50 to 58 and overclaim language from 15 to 23; these are useful monitoring signals but are not, this week, tied to a clear PSP self-management failure.

5. Recommended actions

1. Update treatment-day onboarding with approved, patient-friendly expectations for IV administration, including what the infusion team manages and where patients should direct premedication/flush questions.
2. Add a clear schedule-selection note: patients should follow their prescribed regimen and confirm whether they are on every-3-week or every-6-week dosing.
3. Reinforce human support contacts in onboarding and digital materials for infusion-day and scheduling questions.
4. No proactive outreach is indicated for missed doses, storage, injection technique, or side-effect self-management based on this week’s data.